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Summary
 
The current paradigm of major histocompatibility complex (MHC) and disease association sug-
gests that efficient binding of autoantigens by disease-associated MHC molecules leads to a T
cell–mediated immune response and resultant autoimmune sequelae. The data presented below
offer a different model for this association of MHC with autoimmune diabetes. We used sev-
eral mouse lines expressing different levels of I-A
 
g7
 
 and I-A
 
k
 
 on the nonobese diabetic (NOD)
background to evaluate the role of MHC class II in the previously described NOD T cell auto-
proliferation. The ratio of I-A
 
g7
 
 to I-A
 
k
 
 expression correlated with the peripheral T cell auto-
proliferative phenotype in the mice studied. T cells from the NOD, [NOD 
 
3 
 
NOD.I-A
 
null
 
]F1,
and NOD I-A
 
k
 
 transgenic mice demonstrated autoproliferative responses (after priming with
self-peptides), whereas the NOD.H2
 
h4
 
 (containing I-A
 
k
 
) congenic and [NOD 
 
3 
 
NOD.H2
 
h4
 
congenic]F1 mice did not. Analysis of CD4
 
1
 
 NOD I-A
 
k
 
 transgenic primed lymph node cells
showed that autoreactive CD4
 
1
 
 T cells in the NOD I-A
 
k
 
 transgenic mice were restricted ex-
clusively by I-A
 
g7
 
. Considered in the context of the avidity theory of T cell activation and se-
lection, the reported poor peptide binding capacity of NOD I-A
 
g7
 
 suggested a new hypothesis
to explain the effects of MHC class II expression on the peripheral autoimmune repertoire in
NOD mice. This new explanation suggests that the association of MHC with diabetes results
from “altered” thymic selection in which high affinity self-reactive (potentially autoreactive) T
cells escape negative selection. This model offers an explanation for the requirement of ho-
mozygous MHC class II expression in NOD mice (and in humans) in susceptibility to insulin-
dependent diabetes mellitus.
Key words: nonobese diabetic • insulin-dependent diabetes mellitus • thymic selection • T cell 
receptor repertoire • major histocompatibility complex and disease
 
M
 
ost human autoimmune diseases, such as type I IDDM
and rheumatoid arthritis, are polygenic in nature (1),
making it important to develop animal models of disease-
locus–related immune function in polygenic diseases. The
nonobese diabetic (NOD)
 
1
 
 mouse is a model of complex,
polygenic disease, in which multiple alleles interact to pro-
duce an autoimmune phenotype (2). Of the 18 insulin-
dependent diabetes (Idd) loci identified to date in NOD
mice, the strongest contribution to disease is from Idd1,
which maps to the MHC region and consists of the MHC
class II molecule (I-A
 
g7
 
; reference 2) and possibly a second
gene product (3). The MHC class II molecules are central
to the autoimmune processes, but their exact role has re-
mained controversial. Homozygous I-A
 
g7
 
 expression has
been shown to be necessary, although not sufficient, for the
development of diabetes. In one report, transgenic expres-
sion of IL-10, in combination with I-A
 
g7
 
 homozygosity but
in the absence of other NOD alleles, was sufficient to in-
duce diabetes (4). The association between MHC haplotype
and autoimmune diseases in general has been established
for over two decades (5). Although several mechanisms to
explain this association have been proposed, the actual
mechanism(s) remains unclear (6). Genetic linkage associa-
tion with diabetes in humans and mice is particularly strik-
ing in the requirement for MHC class II homozygosity.
Approximately 96% of North American type I diabetics are
homozygous for expression of the DQ
 
b
 
 57 non-ASP hap-
lotype (7, 8). Similarly, NOD mice are homozygous for a
 
1
 
Abbreviations used in this paper:
 
 HEL, hen egg lysozyme; Idd, insulin-
dependent diabetes; MM, mouse myoglobin; NOD, nonobese diabetic;
PI, propidium iodide; SWM, sperm whale myoglobin.
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non-ASP amino acid, serine, at position 57 of the murine
counterpart of DQ
 
b
 
, I-A
 
g7
 
 (9). NOD F1 mice, heterozy-
gous for non-ASP I-A
 
b
 
 57, demonstrate at most only 
 
z
 
3%
incidence of diabetes, whereas 
 
.
 
95% of diabetic NOD F2
mice (from various breedings) are H-2
 
g7
 
 homozygotes (10–
12). This requirement for MHC class II homozygosity
must be explained in any model of the role of I-A
 
g7
 
 in the
pathogenesis of IDDM. The association of an MHC class II
molecule (requiring a non-ASP amino acid at 
 
b
 
 chain posi-
tion 57) with autoimmune diabetes has been attributed pre-
viously to high affinity binding of “diabetogenic” peptides
by the MHC molecules (13, 14). However, it is unclear why
a twofold decrease in the cell surface expression of MHC
class II (from homozygous to heterozygous) results in a 
 
$
 
30-
fold decrease in disease incidence if the non-ASP MHC class
II molecule functions as a “good” peptide binder.
We previously reported that immunization of NOD
mice with self-peptides in CFA disrupted self-tolerance, al-
lowing CD4
 
1
 
 MHC class II–restricted T cells to recognize
and proliferate in response to endogenously processed and
presented self-peptides on APCs from naive mice (referred
to as “autoproliferation”) (15). We report here that quanti-
tative variation of expression of the NOD MHC class II,
I-A
 
g7
 
, in relation to a second class II, I-A
 
k
 
 (on a genetic back-
ground in which all the other NOD Idd loci except Idd1
are held constant), has a profound effect on the peripheral
CD4
 
1
 
 T cell autoimmune repertoire. The analysis of pe-
ripheral T cell responses to self-peptides in the different
mice (autoproliferation), combined with the demonstration
of quantitative differences in the expression of MHC class
II gene products, supports the idea of defective thymic se-
lection as a basis for the autoreactive peripheral T cell rep-
ertoire in NOD mice. The report that the NOD I-A
 
g7
 
molecule is a poor peptide binder (16), when considered in
the context of an avidity theory of T cell thymic selection,
suggests a unifying explanation for the NOD phenotype
and provides a rationale for the requirement of MHC class
II homozygosity in autoimmune diabetes.
 
Materials and Methods
 
Mice.
 
The following mice were bred and housed in the
Stanford Medical School Department of Comparative Medicine
(DCM) under specific pathogen-free conditions: NOD.H2
 
h4
 
N6F16 congenic (reference 17; hereafter designated NOD.I-A
 
k
 
),
B10.NOD-H2
 
g7
 
Idd10
 
 N7F16 congenic (reference 18; hereafter
designated B10.H2
 
g7
 
) (both gifts of Drs. Linda Wicker and Larry
Peterson, Merck and Co., Inc., Whitehouse Station, NJ); [NOD 
 
3
 
NOD.I-A
 
null
 
]F1 (
 
2
 
/g7; gift of Ms. Ann Herman, Stanford Uni-
versity School of Medicine); and NOD I-A
 
k
 
 transgenic (gift of
Dr. Robyn Slattery, DNAX, Palo Alto, CA). Mice were used be-
tween the ages of 6 and 12 wk (prediabetic). NOD and [NOD 
 
3
 
NOD.I-A
 
k
 
]F1 mice were bred and housed in the DCM.
 
Antigen Proliferation Assays.
 
Peptides mouse myoglobin (MM)
69–78, and MM110–121, sperm whale myoglobin (SWM) 110–
121, hen egg lysozyme (HEL) 46–61, and TCR V
 
b
 
8.2 38–60
were prepared and HPLC-purified by either the Protein and Nu-
cleic Acid Facility, Beckman Center, Stanford University, or by
Dr. Jonathan Rothbard, Stanford University. Mice were immu-
 
nized intradermally at the base of the tail with an emulsion of ei-
ther 5
 
3
 
 CFA (IFA plus 10 mg/ml of heat-killed 
 
Mycobacterium tu-
berculosis
 
, H37RA; Difco, Detroit, MI) alone, or 100 
 
m
 
g of
peptide suspended 1:1 in Dulbecco’s PBS and mixed with an
equal volume of CFA. The mixtures were vortexed for 45 s, then
emulsified via sonification before use. 6–14 d after immunization,
draining inguinal lymph node cells were removed and single cell
suspensions were prepared. 5 
 
3 
 
10
 
5
 
 cells were incubated in 96-
well flat-bottomed plates in either T cell media alone or with ti-
trated doses of antigen or PPD. T cell media consisted of RPMI
1640 supplemented with 2 mM 
 
l
 
-glutamine, penicillin/strepto-
mycin, nonessential amino acids, sodium pyruvate, and 10 mM
Hepes Buffer (GIBCO BRL, Gaithersburg, MD), 50 mM 2-ME
(Sigma Chemical Co., St. Louis MO), and 0.5% normal mouse
serum. After 72 h of culture (at 37
 
8
 
C, 6% CO
 
2
 
), cells were pulsed
with 1 
 
m
 
Ci of [
 
3
 
H]thymidine and harvested 18 h later. For use as
naive APCs, peripheral lymph nodes from naive NOD, NOD.I-
A
 
k
 
, and [NOD 
 
3 
 
NOD.I-A
 
k
 
]F1 mice were obtained and single
cell suspensions were made and irradiated with 3,300 rads.
 
Minimacs Purification of CD4 Cells.
 
Single cell suspensions of
freshly isolated lymph node cells were counted and incubated
with anti-CD4 magnetic microbeads (10 
 
m
 
l beads per 10
 
7
 
 cells;
Miltenyi Biotec, Auburn, CA) for 15 min at 4
 
8
 
C, washed, and
purified by passing through magnetic flow columns. The CD4
 
1
 
cells were counted and 3 
 
3 
 
10
 
5
 
 cells were plated with 10
 
6
 
 naive
lymph node cells. After 72 h of culture, the cells were pulsed and
counted as above.
 
FACS Analysis of Peripheral Lymph Node Cells.
 
For analysis of
peripheral B cell MHC class II expression, single cell suspensions
of peripheral lymph node cells were obtained from naive mice,
counted, and incubated with optimal concentrations of anti-B220
FITC alone or in combination with anti-CD3 FITC and anti-
Mac-1 FITC (PharMingen, San Diego, CA) and 39J biotin (anti-
I-A
 
a
 
k
 
)
 
 
 
or 10.3.6 biotin (anti-I-A
 
b
 
g7
 
 and A
 
b
 
k
 
) (PharMingen) in
FACS buffer (Dulbecco’s PBS plus 2% FCS) for 15 min at 4
 
8
 
C.
The cells were then washed and stained in a second step with
Streptavidin PE (Caltag Labs., Burlingame, CA) for 15 min at
4
 
8
 
C. The cells were washed and resuspended for FACS
 
Ò
 
 analysis
in FACS buffer with propidium iodide (PI). The data was ana-
lyzed using the Herzenberg Desk facility plus Flowjo (Tree Star,
Inc., San Carlos, CA) on a Power Macintosh. All B220
 
1
 
PI
 
2
 
 cells
were gated for display of MHC class II histograms.
 
FACS
 
Ò
 
 Analysis of Thymic Cells.
 
For analysis of thymic den-
dritic cells, thymi were dissected, placed into a solution of 0.5
mg/ml Collagenase D (Boehringer Mannheim, Indianapolis, IN)
in Dulbecco’s PBS/Hepes, and injected with the Collagenase so-
lution. The thymi were then diced using forceps and scissors, and
incubated in the collagenase solution for 45–60 min at 37
 
8
 
C. The
thymi were prepared in single cell suspensions by crushing with a
syringe and passing through a plastic mesh cell strainer. The cells
were washed with tissue culture medium (TCM)/10% FCS, pel-
leted, resuspended in 20 ml TCM/10% FCS, and placed into cul-
ture at 37
 
8
 
C for 2 h. In some experiments the adherent/nonadher-
ent populations were separated at this point, followed by culture
overnight of the adherent population and subsequent splitting of
nonadherent/adherent cell populations; in other experiments the
cells were directly fractionated. In both cases, the cells were pel-
leted, counted, and stained with anti-CD11c Minimacs magnetic
beads (Miltenyi Biotec) at 10 
 
m
 
l per 10
 
7
 
 cells for 15 min at 4
 
8
 
C.
The cells were then passed through a Minimacs column for posi-
tive selection. The positively selected cells were stained with anti-
CD11c PE (PharMingen) and either AMS 32.1 FITC (PharMin-
gen) or 39J biotin at optimal concentration for 15 min at 4
 
8
 
C. 
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Figure 1. The effect of varying MHC on the autoproliferative response. (A) NOD and NOD.I-Ak mice were immunized with self-peptide (TCR) in
CFA; 8 d later draining lymph node responses were analyzed in media alone for autoproliferation. One representative experiment of at least four is
shown. (B) NOD I-Ak transgenic and [NOD 3 NOD.I-Ak]F1 mice were immunized with a self-peptide (TCR) in CFA; 8 d later the draining lymph
node cells were cultured and analyzed for response in media alone. One representative experiment of four is shown. (C) NOD I-Ak transgenic mice were
immunized as in A and B. The CD41 cells from primed lymph nodes were purified by CD4 Minimacs bead columns, then cultured with naive NOD or
NOD.I-Ak lymph nodes as APCs in media alone. The transgenic CD41 cells autoproliferated only in response to NOD APCs. One representative exper-
iment of four is shown.
 
Control staining with anti-CD4 PE and anti-CD8 FITC (Caltag
Labs.) was also performed to identify thymocytes. The cells were
washed and the 39J bound cells were stained in a second step
with Streptavidin-FITC (Caltag Labs.). The cells were washed
and suspended in FACS buffer with PI for analysis by flow cy-
tometry. The data were analyzed using Flowjo with the following
parameters: PI
 
2
 
 cells were gated out, and large cells were ana-
lyzed for CD11c and class II expression. The CD11c MHC class
II high cell population was gated identically across samples for
display of MHC expression. Statistical analysis was performed on
Excel (Microsoft Corp., Redmond, WA).
 
Results
 
After Immunization with Self-peptide, NOD Mice Demon-
strate an Autoproliferative Response, Whereas NOD.I-A
 
k
 
 Mice
Do Not.
 
Our previous results showed that NOD mice re-
sponded to immunization with self-peptides in CFA by de-
veloping autoproliferative T cells in the draining lymph
node, i.e., primed CD4
 
1
 
 T cells that proliferated in re-
sponse to naive APCs expressing the endogenously pro-
cessed and presented self-antigens used for priming (15).
We first explored the role of MHC in the autoproliferative
response by using NOD and NOD.I-A
 
k
 
 mice (17). After
immunization with a self-peptide (TCR V
 
b
 
8.2 amino ac-
ids residues 38–60), NOD but not NOD.I-A
 
k
 
 mice exhib-
ited autoproliferation (Fig. 1 
 
A
 
). NOD.I-Ak mice also
showed no autoproliferative response after immunization
with several other self-peptides including MM110–121 and
MM69–78 (data not shown), which have previously been
demonstrated to induce autoproliferation in NOD mice
(15). These data demonstrated that introgression of a por-
tion of a non-NOD MHC onto a background of NOD
genes either prevented the autoproliferative response, or,
conversely that the NOD background genes, in the ab-
sence of the NOD MHC, were insufficient for an autopro-
liferative response.
NOD I-Ak Transgenic Mice Demonstrate an Autoproliferative
Response, Whereas [NOD 3 NOD.I-Ak]F1 Mice Do Not.
The loss of an autoproliferative phenotype in the NOD.I-Ak
mice could represent a dominant effect of I-Ak expression.
To examine this, we bred [NOD 3 NOD.I-Ak]F1 mice
and immunized them with the same set of self-peptides.
The [NOD 3 NOD.I-Ak]F1 mice failed to demonstrate
autoproliferation after immunization with the set of self-
peptides previously shown to induce autoproliferative re-
sponses in NOD mice (reference 15; Fig. 1 B), responding
in each case in a manner similar to the parental NOD.I-Ak
mice. These results were consistent with a dominant effect
of I-Ak. [NOD 3 NOD.I-Ak]F1 mice express I-Ag7 and
I-Ak at heterozygous levels on a NOD background. To
further characterize the possible effect of I-Ak expression in
the presence of I-Ag7, we studied autoproliferation in
NOD I-Ak transgenic mice (19). The NOD I-Ak trans-
genic mice (females) develop diabetes (at reduced levels,
z20–40% incidence compared with female NOD mice
z80%) and their T cells can transfer diabetes to NOD/scid
mice (20). The expression of I-Ak as a transgene, in the
presence of I-Ag7, did not inactivate the autoproliferative
response (Fig. 1 B). These data were originally difficult to
interpret, since both the NOD I-Ak transgenic mice and
the [NOD 3 NOD.I-Ak]F1 mice express I-Ag7 and I-Ak
on a NOD background. Thus, a simple model of a domi-2270  MHC Class II Expression and Autoproliferation in NOD Mice
nant I-Ak effect could not explain the loss of the autoprolif-
erative phenotype in the F1 compared with the transgenic
mice.
The Autoproliferative Response in NOD I-Ak Transgenic
Mice Is Restricted Solely by I-Ag7. If the peripheral T cell
repertoire selection in NOD I-Ak transgenic mice was nor-
mal on I-Ak but defective on the I-Ag7 gene product, the
autoproliferating T cells from the NOD I-Ak transgenic
mice would recognize self-peptide only with I-Ag7 restric-
tion, not when presented by I-Ak APCs. To test this hy-
pothesis, we purified the CD41 T cells from the draining
lymph nodes of NOD I-Ak transgenic mice immunized
with self-TCR peptide in CFA and cultured them with ei-
ther NOD or NOD.I-Ak lymph node cells from naive
mice as APCs. Purified CD41 T cells from NOD I-Ak
transgenic mice autoproliferated in response to the APCs
from naive NOD mice (recognizing endogenously pro-
cessed and presented self-antigen) but showed no response
to the APCs from naive NOD.I-Ak mice (Fig. 1 C). Thus,
the NOD I-Ak transgenic T cell autoproliferative response
was entirely I-Ag7 restricted.
[NOD 3 NOD.I-Anull]F1 mice Show an Autoproliferative
Response, whereas [NOD 3 NOD.I-Ak]F1 Mice Show no Re-
sponse to Immunization with Self-peptide MM110–121. It re-
mained possible that the lack of an I-Ag7–restricted auto-
proliferative response to immunization with self-peptide in
the [NOD 3 NOD.I-Ak]F1 mice resulted either from in-
sufficient I-Ag7 expression (a gene dose effect), or from het-
erozygous expression of a (dominant) non-NOD allele in
the introgressed H-2k MHC region. We disproved these
possibilities by using [NOD 3 NOD.I-Anull]F1 mice, which
express heterozygous levels of I-Ag7 in the absence of a
competing MHC class II gene product, but also (like the
[NOD 3 NOD.I-Ak]F1 mice) possess a significant portion
of introgressed non-NOD MHC. We have previously
shown that NOD mice mount an autoproliferative response
to self-peptide MM110–121 (15). NOD.I-Ak mice showed
no response to this peptide (data not shown). [NOD 3
NOD.I-Ak]F1 mice showed no response to immunization
with MM110-121, resembling the parental NOD.I-Ak re-
sult (Fig. 2). In contrast, [NOD 3 NOD.I-Anull]F1 mice
autoproliferated after immunization with MM110–121
(Fig. 2). This result demonstrated that the quantitative ratio
of expression of I-Ag7 in relation to another MHC class II
gene product, rather than the absolute amount of I-Ag7,
must be critical in forming the bias in the peripheral T cell
response in [NOD 3 NOD.I-Ak]F1 and NOD I-Ak trans-
genic mice. The autoproliferative response of the [NOD 3
NOD.I-Anull]F1 mice, despite the presence of a hetero-
zygous introgressed non-NOD MHC region, also strongly
suggested that the lack of autoproliferative response in the
[NOD 3 NOD.I-Ak]F1 mice was not due to a dominant
non-MHC class II gene product in the H-2k region.
FACS Analysis of Splenic and Thymic APC MHC class II a
and b Chain Expression Discriminates NOD I-Ak Transgenic
and [NOD 3 NOD.I-Ak]F1 Mice. To understand how
mice with identical NOD background genes (apart from
the introgressed Idd1 locus) and the same MHC class II el-
ements could differ so dramatically in their response to im-
munization with the same self-peptides, we analyzed the
expression levels of the I-Ag7 and I-Ak in the NOD I-Ak
transgenic and [NOD 3 NOD.I-Ak]F1 mice. Peripheral
lymph node cells were isolated from the mice, stained with
B220 and 39J (I-Aak), and analyzed by flow cytometry.
PI1 cells were gated out and B2201 cells were displayed for
their MHC class II I-Aak levels (Fig. 3 A). The NOD I-Ak
transgenic and the [NOD 3 NOD.I-Ak]F1 mice differed
in two ways. First, the NOD I-Ak transgenic B2201 cells
that were positive for I-Aak consistently expressed from
two- to fourfold less I-Ak mean channel fluorescence than
the [NOD 3 NOD.I-Ak]F1 mice, under identical staining
conditions. Second, the NOD I-Ak transgenic mice repro-
ducibly showed a subset of B2201 cells that lacked appre-
ciable I-Aak expression (Fig. 3 A, second row, left column).
Whole peripheral blood FACSÒ studies using a different
antibody, AMS 32.1 (which binds I-Abg7 but not I-Abk),
as well as 39J, showed that the ratio of I-Ag7 to I-Ak in the
NOD I-Ak transgenic mice was reproducibly fourfold
greater than the I-Ag7 to I-Ak ratio in the [NOD 3
NOD.I-Ak]F1 mice. This was due to the “expected” two-
fold reduction in the I-Ag7 (AMS) expression in the [NOD 3
NOD.I-Ak]F1 mice (compared with the NOD I-Ak trans-
genic mice; data not shown), combined with the unex-
pected twofold decrease in I-Ak expression in the NOD
I-Ak transgenic (compared with the [NOD 3 NOD.I-Ak]
mice). Whole blood mononuclear cells from NOD I-Ak
transgenic mice, in contrast to B2201 cells, did not show a
subpopulation of I-Ag71, I-Ak- cells.
We next examined I-Ak expression in the NOD I-Ak
transgenic versus [NOD 3 NOD.I-Ak]F1 thymic APCs.
Dendritic cells are known to be critical in thymic selection
events (21, 22). We isolated thymic dendritic cells from
[NOD 3 NOD.I-Ak]F1 and NOD I-Ak transgenic thymi,
using a combination of collagenase digestion, adherence,
Ca21 free buffer (23, 24), and, finally, positive selection
with CD11c-coated magnetic beads on a Minimacs col-
umn. The resultant population of cells was stained with
CD11c and MHC class II antibodies and analyzed by flow
cytometry. Data presented in Fig. 3 B show the MHC class
II I-Aak (39J) expression of the NOD I-Ak transgenic and
Figure 2. Autoproliferative re-
sponse in [NOD 3 NOD.I-Anull]
F1 versus [NOD 3 NOD.I-Ak]
F1 mice. [NOD 3 NOD.I-Ak]
F1 (n 5 5) and [NOD 3
NOD.I-Anull]F1 (n 5 2) mice
were immunized with self-peptide
MM110-121 in CFA; 8 d later
draining lymph nodes were cul-
tured in media alone.2271 Ridgway et al.
[NOD 3 NOD.I-Ak]F1 thymic CD11c1 cells. The thy-
mic CD11c1 NOD I-Ak transgenic I-Aak expression re-
producibly showed an approximately twofold reduction in
the I-Aak (39J1) levels compared with that of the [NOD 3
NOD.I-Ak]F1 mice. Consistent with the peripheral ex-
pression, the NOD I-Ak transgenic thymic cells also
showed approximately twofold greater expression of I-Ag7
(AMS mean channel fluorescence) than the [NOD 3
NOD.I-Ak]F1 cells (data not shown).
I-Ak–restricted T Cell Responses in the NOD I-Ak Transgenic
Mouse. A possible explanation of the effect of quantita-
tively different expression of I-Ak in the NOD I-Ak trans-
genic and [NOD 3 NOD.I-Ak]F1 mice was that the level
of I-Ak in the NOD I-Ak transgenic mouse was insufficient
to mediate some undetermined I-Ak–restricted T cell
event. We examined this possibility in two ways. First,
NOD I-Ak transgenic CD41 T cells were shown to be
broadly tolerant to I-Ak, despite the decreased I-Ak expres-
sion relative to I-Ag7 (compared with the [NOD 3
NOD.I-Ak]F1 mouse; Fig. 1 B); i.e., there was no MLR
reaction of NOD I-Ak transgenic CD41 cells to NOD.I-Ak
APCs. Second, as previously reported for these NOD I-Ak
transgenic mice (17), they showed an intact T cell response
to immunization with a peptide, HEL 46–61, which binds
I-Ak, whereas NOD mice showed no response (data not
shown). In these two assays, we did not detect a gross de-
fect in I-Ak peripheral T cell immune function in the
NOD I-Ak transgenic mice.
[NOD 3 NOD.I-Ak]F1 Mice Demonstrate a Poor Response
to the I-Ag7–restricted Foreign Peptide SWM110–121, Al-
though [NOD 3 NOD.I-Ak]F1 Peripheral APCs Can Effec-
tively Bind and Present SWM110–121. We addressed the
crucial question of whether the demonstrable MHC effect
controlling the T cell restriction bias was central (thymic) or
peripheral by exploring the response of various mice to im-
munization with a foreign peptide (SWM 110–121) that
differs from the self-peptide MM110–121 by 5 amino acids,
is restricted by I-Ag7, and does not bind I-Ak. NOD mice
responded strongly to immunization with SWM110–121
(Fig. 4 A). NOD I-Ak transgenic mice also responded to
SWM 110–121, whereas NOD.I-Ak mice showed no re-
sponse (data not shown). Surprisingly, however, the re-
sponse to SWM110–121 of [NOD 3 NOD.I-Ak]F1 mice
was much less than the expected semidominant level when
compared with the NOD SWM110–121 response (Fig. 4
A). To demonstrate that the poor (or absent) response to
Figure 3. MHC class II expression levels in peripheral and thymic
APCs. (A) I-Aak mean channel fluorescence (numbers in the right col-
umn) of B2201 cells from naive peripheral lymph node cells (shown gated
in the left column) of NOD, NOD I-Ak transgenic, NOD.I-Ak, and
[NOD  3  NOD.I-Ak]F1 mice. One representative of three experiments is
shown. (B) I-Aak mean (left) and median (right) channel fluorescence of
NOD I-Ak transgenic and [NOD 3 NOD.I-Ak]F1 thymic CD11c1 cells
(shown gated in the top). One representative experiment of three is
shown.2272  MHC Class II Expression and Autoproliferation in NOD Mice
SWM110–121 in the [NOD 3 NOD.I-Ak]F1 mice did not
represent a general inability of the [NOD 3 NOD.I-Ak]F1
I-Ag7 to bind or present this peptide, we derived a SWM110–
121 reactive line from draining lymph nodes of NOD I-Ak
transgenic mice immunized with SWM110–121 and as-
sayed the response of T cells from this line to SWM110–
121 using irradiated NOD or [NOD 3 NOD.I-Ak]F1
lymph node cells as an APC source. The [NOD 3 NOD.I-
Ak]F1 APCs efficiently presented SWM110–121 to the
NOD I-Ak transgenic T cells, at approximately semidomi-
nant efficacy (z50% the response of the homozygous
APCs), compared with NOD APCs (Fig. 4 B), demonstrat-
ing that the [NOD 3 NOD.I-Ak]F1 peripheral I-Ag7 had
no intrinsic defect in binding or presenting SWM 110–121.
It remained possible that the [NOD 3 NOD.I-Ak]F1
mice had a defect in I-Ak as well as I-Ag7 responses, i.e., that
there was a global defect in T cell responses in these mice.
To test this, we primed NOD.I-Ak and [NOD 3 NOD.I-
Ak]F1 mice with an I-Ak–restricted peptide, HEL 46–61. In
contrast to their lack of response to I-Ag7 restricted peptides
(SWM 110–121, MM110–121, MM69–78, and TCR
peptide), the [NOD 3 NOD.I-Ak]F1 mice demonstrated
a semidominant response (z50% of the homozygous re-
sponse) to HEL 46–61 when compared with the parental
(homozygous MHC class II–expressing) NOD.I-Ak(Fig. 4
C). Thus, the poor (or absent) responses of [NOD 3
NOD.I-Ak]F1 mice to I-Ag7–restricted peptides did not re-
flect a global defect in CD41 T cell responses in these mice.
B10.H297 Congenic Mice Lack the Autoproliferative Pheno-
type. These results demonstrated that the presence of the
autoproliferative phenotype was critically dependent upon
the quantitative ratio of MHC class II gene expression
when the NOD background outside the MHC region was
fixed. We next asked whether homozygous I-Ag7 MHC
expression was both necessary and sufficient for the auto-
proliferative phenotype. We immunized mice expressing
homozygous I-Ag7 on a non-NOD background (B10.H2g7
mice) with self-peptide in CFA. The draining lymph node
cells of these mice did not autoproliferate (Fig. 5). Thus,
homozygous I-Ag7 MHC expression is necessary, but not
sufficient, for the autoproliferative phenotype.
Discussion
Using several lines of “NOD” mice with identical non-
MHC NOD background genes, lacking I-E expression and
varying in the relative expression of I-Ag7 and I-Ak, we have
studied the quantitative effect of varying MHC class II gene
expression on the peripheral T cell response. We have found
that the homozygous MHC haplotype determines the re-
sponse to self-peptides (NOD and NOD.I-Ak responses in
Fig. 1 A). When two different I-A molecules are coex-
pressed on the NOD background, the result of immuniza-
tion with a self-peptide can vary from an autoproliferative
response to no response (NOD I-Ak transgenic versus
[NOD  3  NOD.I-Ak]F1; Fig. 1 B). The critical determinant
of the differences in autoproliferative response in the mixed
MHC mice to self-peptide immunization was the relative
expression of the two MHC class II molecules (Fig. 3, A and
B). The NOD I-Ak transgenic mice consistently demon-
Figure 4. Response to and presentation of I-Ag7 (SWM110–121) or
I-Ak (HEL 46–61) restricted peptides by [NOD 3 NOD.I-Ak]F1, NOD,
and NOD.I-Ak mice. (A) NOD and [NOD 3 NOD.I-Ak]F1 mice were
primed with SWM110–121; 8 d later the draining lymph nodes were as-
sayed for dose response to SWM110–121. The mean response 6 SEM of
10 (NOD) and 7 ([NOD 3 NOD.I-Ak]F1) separate assays is displayed. (B)
Naive irradiated NOD or [NOD 3 NOD.I-Ak]F1 lymph node cells were
used as APCs for a NOD I-Ak transgenic SWM110–121 T cell reactive
line. (C) NOD.I-Ak and [NOD 3 NOD.I-Ak]F1 mice were primed with
HEL 46–61 in CFA; 8 d later the draining lymph node cells were assayed
for response to HEL 46–61.2273 Ridgway et al.
strated two- to fourfold less I-Ak expression in thymic and
peripheral APCs than did the [NOD 3 NOD.I-Ak]F1 mice.
The ratio of I-Ag7 to I-Ak in the NOD I-Ak transgenic mice
was at least fourfold greater than that in the [NOD 3
NOD.I-Ak]F1 mice. The localization of the thymus as the
site of the effect of the altered MHC ratio on the peripheral
T cell response was demonstrated by studying the responses
of [NOD 3 NOD.I-Ak]F1 mice to peptides that were not
presented by (don’t bind to) I-Ak, and to which responses
were lacking in the NOD I-Ak congenic parent, i.e.,
SWM110–121 and MM110–121. The poor [NOD 3
NOD.I-Ak]F1 SWM response (Fig. 4 A) could not be due
to poor peripheral binding of I-Ag7 to SWM110–121, since
the [NOD 3 NOD.I-Ak]F1 mice were efficient at binding
and presenting SWM110–121 to SWM reactive transgenic
T cells (Fig. 4 B). The poor [NOD 3 NOD.I-Ak]F1 SWM
response also could not be attributed to insufficient quantity
of I-Ag7 (gene dose effect), since an F1 dose of I-Ag7 in the
absence of a competing “good binding” MHC (in the
[NOD 3 NOD.I-Anull]F1 mice) allowed an autoprolifera-
tive response to MM110–121  (a response lacking in the
[NOD 3 NOD.I-Ak]F1 mice) (Fig. 2). The autoprolifera-
tive response of the [NOD 3 NOD.I-Anull]F1 mice also
strongly suggested that the poor [NOD 3 NOD.I-Ak]F1 re-
sponse was unlikely to be due to a dominant non-MHC class
II gene expressed in the introgressed non-NOD MHC. The
overall response to both self- and foreign peptides in the
[NOD 3 NOD.I-Ak]F1 mice suggested a remarkable skew-
ing of T cell restriction toward the parental I-Ak MHC and
away from the parental I-Ag7 MHC. In the absence of a crit-
ical ratio of I-Ag7 to I-Ak expression, autoreactive T cells did
not appear at high frequency in the [NOD 3 NOD.I-Ak]F1
mice, whereas they did appear in the NOD I-Ak transgenic
and [NOD 3 NOD.I-Anull]F1 mice. We have not seen an
autoproliferative response in any mouse strain other than
NOD, suggesting it is a unique response of NOD mice to
immunization with self-peptides. Additionally, Kanagawa et
al. have recently demonstrated (by limiting dilution analysis)
that mice expressing I-Ag7 have a much higher incidence of
autoreactive T cells than do mice expressing other MHC
haplotypes (25), strongly suggesting that the results reported
here reflect the general T cell repertoire phenotype of I-Ag7
versus non–I-Ag7 mice.
The simplest explanation of the data presented here impli-
cates I-Ag7 in defective thymic selection in a manner directly
related to its quantitative expression. In [NOD 3 NOD.I-
Ak]F1 mice, the ratio of MHC expression appears insuffi-
cient for effective selection of the I-Ag7–restricted peripheral
repertoire. The increased ratio of I-Ag7 to I-Ak in the NOD
I-Ak transgenic mice allows selection on I-Ag7, but permits
escape of T cells with the capacity to recognize and prolifer-
ate in response to endogenously processed and presented
self-antigens (autoproliferation), as does expression of I-Ag7
at the homozygous level in NOD mice and at the heterozy-
gous level in absence of a second MHC (in the [NOD 3
NOD.I-Anull]F1 mice), suggesting inefficient negative selec-
tion. These results are consistent with previous reports that
raised the possibility of defective thymic selection in the
NOD mouse. Serreze and Leiter showed that reconstitution
of diabetes-resistant [NOD 3 NON]F1 mice with NOD
bone marrow cells eliminated diabetes resistance (26). More-
over, they showed that congenic F1 mice, heterozygous for
I-Ag7 and H-2nb1 MHC products, were susceptible to dia-
betes if reconstituted with NOD bone marrow, whereas re-
constitution with an F1 bone marrow resulted in diabetes
resistance (26). These results (with an endpoint of diabetes
incidence) are compatible with the data presented here on
the quantitative effect of MHC class II expression on an auto-
proliferative T cell response. Deluca et al. published that
NOD mice showed the highest ratio of all mouse strains
studied of single positive to double positive cells in fetal thy-
mic organ culture, suggestive of less stringent thymic nega-
tive selection (27). Forsgren et al. showed that NOD:B6
allophenic chimeras must express .50% NOD MHC pheno-
type in their lymphoid compartment, as well as express the
NOD haplotype in the thymic cortical epithelium, in order
to develop insulitis (28). These data suggest that a prepon-
derance of the NOD MHC in the medullary thymic com-
partment results in defective negative selection (28). Taken
as a whole, the literature suggests defective thymic selection
in the NOD mouse, and the results presented here suggest
that the selection defect may be mediated in a quantitative
fashion by relative levels of MHC class II expression.
A mechanism of defective thymic selection by I-Ag7 is
not established here. However, the report that I-Ag7 is un-
stable and a “poor peptide binder” (16) suggests a mecha-
nistic explanation when considered in the context of an
avidity theory of T cell activation and thymic selection
(29–32). Carrasco-Marin et al. showed that I-Ag7 was un-
stable in SDS-PAGE analysis, and that this instability corre-
lated with decreased cell surface expression, and found that
the peptide binding of I-Ag7 at acidic pH was too weak to
allow kinetic analysis (16). MHC class II instability and
poor peptide binding would have a profound effect on thy-
mic selection by decreasing the effective dose of I-Ag7
MHC–self-peptide (ligand) on the selecting APC surface.
In an avidity model of thymic selection (29–32), the net re-
sult of universal poor peptide binding by I-Ag7 (diminished
ligand) would be a global increase in TCR affinity for both
positive and negative selection in I-Ag7 homozygous mice.
In the [NOD 3 NOD.I-Ak]F1 mouse, the poor peptide
binding of I-Ag7, combined with a decreased I-Ag7 dose,
Figure 5. Response of B10.H2g7
mice to immunization with self-
peptide. B10.H2g7 mice were
primed with self-peptide TCR
in CFA; 8 d later the draining
lymph node cells were assayed
for response in media 6 antigen.
The mean of the response of
three separate assays 6 SEM is
shown.2274  MHC Class II Expression and Autoproliferation in NOD Mice
might dramatically decrease the amount of [I-Ag7–self-pep-
tide] available for I-Ag7–mediated selection, creating func-
tional “I-Ag7 clonal ignorance” (33) in the thymus. The
presence of the good peptide binder, I-Ak, could enhance
the effect by quantitatively superior binding of self-peptides
to I-Ak (“determinant stealing”, reference 34) in the thy-
mic APCs at the time of positive selection. Notably, al-
though the I-Ag7 restricted autoreactive response changes
dramatically from the [NOD 3 NOD.I-Ak]F1 to the
NOD I-Ak transgenic mouse in response to a change in the
effective ratio of I-Ag7/I-Ak, the converse is not true; I-Ak–
restricted immune peripheral function appears to be grossly
intact in the NOD I-Ak transgenic mouse despite a signifi-
cant decrease in I-Ak expression (Fig. 1 C), and I-Ak–
restricted responses in the [NOD 3 NOD.I-Ak]F1 mice are
at the expected semidominant level compared with the
parental NOD.I-Ak mice (Fig. 4 C). Increasing the I-Ag7/
I-Ak ratio (in the NOD I-Ak transgenic mouse) or I-Ag7
homozygosity (NOD mice) could overcome the effect of
I-Ak when compared with the [NOD 3 NOD.I-Ak]F1,
thereby allowing positive selection of I-Ag7–restricted T
cells, while the amount of peptide/I-Ag7 representation in
the thymus might still be insufficient (compared with a
“good” peptide binding MHC) to mediate effective clonal
deletion/negative selection. The result would be the re-
lease into the periphery of I-Ag7–restricted T cells with
higher affinity TCRs than could occur in the thymus of
mice with a “good peptide” binding MHC; the increased
affinity of the T cells being required to compensate for de-
creased MHC–peptide density in order to attain the requi-
site avidity level for selection. (29–32). Once such T cells
reach the periphery, the multiple other NOD Idd genes (2)
would then interact to allow activation and initiation of a
peripheral autoimmune process. That this progression from
a high affinity self-reactive (autoproliferative) T cell reper-
toire to autoimmunity requires more than the “permissive”
MHC selection is supported by the lack of an autoprolifer-
ative response in non-NOD mice expressing homozygous
I-Ag7 in the absence of sufficient other Idd genes (Fig. 5).
One paradox of any model invoking poor thymic I-Ag7
peptide binding in defective thymic selection is how T cells
escaping deletion could be activated in the periphery, since
presumably the same MHC stability defect would be
present. A possible explanation involves pH-dependent dif-
ferential I-Ag7 stability. Carrasco-Marin et al. reported poor
I-Ag7 peptide binding at pH 5.5 (endosomal), whereas
other reports suggested that the binding might be stabilized
at pH 7.0 (16, 35). If thymic selection primarily used
endogenously processed peptides, the endosomal defect
could predominate. In the periphery, however, I-Ag7 on
the cell surface (closer to pH 7.0) at the site of inflamma-
tion might stably bind exogenous self-antigens, allowing
activation of potentially autoreactive T cells that escaped
from thymic selection. However, these theories remain
speculative until the normal physiology of thymic selec-
tion, and the differences between thymic and peripheral ac-
tivation of T cells are further elucidated. Nonetheless, our
data support defective thymic selection as a mechanism of
the unique I-Ag7–controlled autoproliferative response.
The model presented here also offers an explanation for the
puzzling observation that human and murine diabetes, almost
uniquely amongst autoimmune diseases correlated with MHC
molecules, require homozygous MHC class II expression for
the development of disease. The data on the [NOD 3
NOD.I-Ak]F1, NOD I-Ak transgenic, and NOD peripheral
immune responses suggest that a homozygous dose of MHC
class II NOD I-Ag7, and possibly human HLA-DQ3.2 (36) is
(usually) required for selection of a sufficiently large popula-
tion of T cells to ultimately mediate autoimmunity. MHC
class II heterozygosity would allow a major skewing in the
MHC restriction of the expressed peripheral T cell repertoire
to a non-self-reactive repertoire due to the role played in thy-
mic selection by the “non-susceptible” MHC class II allele.
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